Home > Insider Trading > Filing (0000950170-24-107536)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1776111	Mbx Biosciences Inc.	MBX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1341382	N James Topper	601 Union Street, Suite 3200 Seattle WA 98101	No	No	No	No
1790811	Fhmls X, L.l.c.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	No	No
1790879	Frazier Life Sciences X, L.p.	C/O Mbx Biosciences, Inc. 11711 N. Meridian Street, Suite 300 Carmel IN 46032	No	No	No	No
1790880	Fhmls X, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-09-16	3,927,774	$0.00	3,927,774	No	4	C	Direct
Common Stock	Acquisiton	2024-09-16	625,000	$16.00	4,552,774	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-09-16	18,922,852	$0.00	1,574,005	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2024-09-16	28,297,265	$0.00	2,353,769	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Reflects shares purchased in the Issuer's initial public offering.